VelaVigo, Announces VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/ TROP2 Bispecific Antibody-Drug Conjugate 07.08.2025 - 18:03:22 | prnewswire.co.uk VelaVigo Cayman Limited Denmark Finland Germany Netherlands Sweden United Kingdom New York China View original content:https://www.prnewswire.co.uk/news-releases/velavigo-announces-exclusive-option-agreement-with-avenzo-to-license-a-potential-first-in-class-nectin4trop2-bispecific-antibody-drug-conjugate-302308511.html en | boerse | 67997894 |
